CDER Deputy Director Galson To Head Drug Center For Several Months
This article was originally published in The Tan Sheet
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
You may also be interested in...
Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, will be acting center director during the period when FDA is expected to announce a decision on forced Rx-to-OTC switches
FDA is looking for a new director for its fledgling Office of Drug Safety following the departure of Peter Honig, MD, to Merck
Office of Review Management renamed Office of New Drugs, effective Jan. 13. As of Jan. 1, newly created Office of Pharmacoepidemiology & Statistical Science (OPaSS) will include Office of Biostatistics and Office of Drug Safety (formerly Office of Post-Marketing & Drug Risk Assessment). ODS now houses MedWatch program, medication guides function. OPaSS is headed by Paul Seligman, MD (1"The Tan Sheet" Nov. 12, 2001, p. 16)...